Idarubicin
- Atc Codes:L01DB06
- CAS Codes:57852-57-0#58957-92-9
- PHARMGKB ID:57852-57-0#58957-92-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Zavedos; Belgium: Zavedos; Bulgaria: Zavedos; Cyprus: Zavedos; Czech Republic: Zavedos; Denmark: Zavedos; Estonia: Zavedos; Finland: Zavedos; France: Zavedos; Germany: Zavedos; Greece: Zavedos; Hungary: Zavedos; Ireland: Zavedos; Italy: Zavedos; Latvia: Zavedos; Lithuania: Zavedos; Luxembourg: Zavedos; Netherlands: Zavedos; Poland: Zavedos; Portugal: Zavedos; Romania: Zavedos; Slovakia: Zavedos; Slovenia: Zavedos; Spain: Zavedos; Sweden: Zavedos; UK: Zavedos.
North America
Canada: Idamycin; USA: Idamycin, Idarubicin.
Latin America
Argentina: Idarubicina, Idarrubicina, Zavedos; Brazil: Zavedos; Mexico: Idamycin, Idaralem, Idarubicina.
Asia
Japan: Idamycin.
Drug combinations
Chemistry
Idarubicin Hydrochloride: C~26~H~27~NO~9~ HCl. Mw: 533.95. (1) 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis)-; (2)(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside, hydrochloride. CAS-57852-57-0; CAS-58957-92-9 (idarubicin)(1987).
Pharmacologic Category
Antineoplastic Agents; Cytotoxic Antibiotics and Related Substances. Anthracycline. Antibiotic. (ATC-Code: L01DB06).
Mechanism of action
Intercalates into DNA and/or inhibits topoisomerase II, resulting in disruption of nucleic acid synthesis.
Therapeutic use
Treatment of acute leukemias, accelerated phase or blast crisis of chronic myelogenous leukemia, breast cancer. Used in combination with other antineoplastic agents for treatment of acute myeloid (myelogenous, nonlymphocytic) leukemia.
Pregnancy and lactiation implications
Unlabeled use
Autologous hematopoietic stem cell transplantation.
Contraindications
Hypersensitivity to idarubicin, other anthracyclines, or any component of the formulation. Bilirubin >5 mg/dL. Pregnancy.
Warnings and precautions
Hazardous agent. May cause severe myelosuppression, hyperuricemia, myocardial toxicity (heart failure, arrhythmias or cardiomyopathies). For I.V. administration only. Use with extreme caution in pre-existing bone marrow suppression from prior treatment or radiation, in pre-existing cardiac disease (may increase risk of cardiotoxicity), and in hepatic or renal impairment.